MEG3 and hepatocellular carcinoma: MEG3 is downregulated in HCC tissues and cell lines, especially by the methylation of its promoter by DNA methyltransferases DNMT1 and DNMT2, and its reduced expression is associated with poor prognosis in HCC patients [103,181].